Table: q1_q4_2023_prescription_drug_wac_increases , manufacturer_name like R*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id manufacturer_name date_reported ndc_number drug_product_description drug_category drug_category_source wac_effective_date wac_increase_amount wac_after_increase patent_expiration_date drug_source_type unit_sales_volume_in_us unit_sales_volume_non_public_indicator cost_increase_factors cost_increase_factors_non_public_indicator change_improvement_description change_improvement_non_public_indicator acquisition_date company_acquired_from acquisition_price acquisition_price_non_public_indicator acquisition_price_comment wac_at_acquisition wac_year_prior_to_acquisition year_drug_introduced_to_market wac_at_intro_to_market supporting_documents general_comments
Rx0000356 Radius Health, Inc. 03/31/2023 70539000101 TYMLOS 80 MCG Pen Brand FDA 01/01/2023 226.64 2515.98 01/10/2040 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Radius believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 03/16/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Radius Health, Inc. did not acquire this product from another manufacturer within the previous five years. As a result, Radius Health has left columns N-U blank because they are not applicable to this product.
Rx0000356 Radius Health, Inc. 03/31/2023 70539000102 TYMLOS 80 MCG Pen / Carton Brand FDA 01/01/2023 226.64 2515.98 01/10/2040 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Radius believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 03/16/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Radius Health, Inc. did not acquire this product from another manufacturer within the previous five years. As a result, Radius Health has left columns N-U blank because they are not applicable to this product.
Rx0000363 Recordati Rare Diseases, inc. 03/31/2023 55292020111 Chemet Oral Capsule 100 MG Package Size 100 Quantity 1 Brand FDA 01/05/2023 178.08 2404.02 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000363 Recordati Rare Diseases, inc. 03/31/2023 55292081155 Cosmegen Intravenous Solution Reconstituted 0.5 MG Package Size 1 Quantity 1 Brand FDA 01/05/2023 234.99 2708.54 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000363 Recordati Rare Diseases, inc. 03/31/2023 55292041005 Cystadrops Ophthalmic Solution 0.37 % Package Size 5 Quantity 1 Brand FDA 01/05/2023 59.62 2046.88 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000363 Recordati Rare Diseases, inc. 06/30/2023 55292032020 Isturisa Oral Tablet 1 MG 20 EA Brand FDA 05/01/2023 275.02 3169.98 10/12/2035 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000363 Recordati Rare Diseases, inc. 06/30/2023 55292032060 Isturisa Oral Tablet 1 MG 60 EA Brand FDA 05/01/2023 825.06 9509.93 10/12/2035 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000363 Recordati Rare Diseases, inc. 06/30/2023 55292032220 Isturisa Oral Tablet 10 MG 20 EA Brand Medispan 05/01/2023 1100.84 12688.66 10/12/2035 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000363 Recordati Rare Diseases, inc. 06/30/2023 55292032260 Isturisa Oral Tablet 10 MG 60 EA Brand Medispan 05/01/2023 3302.25 38065.96 10/12/2035 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000363 Recordati Rare Diseases, inc. 06/30/2023 55292032120 Isturisa Oral Tablet 5 MG 20 EA Brand FDA 06/16/2023 6091.72 15849.88 10/12/2035 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000363 Recordati Rare Diseases, inc. 06/30/2023 55292032160 Isturisa Oral Tablet 5 MG 60 EA Brand FDA 06/16/2023 18275.18 47549.65 10/12/2035 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000363 Recordati Rare Diseases, inc. 03/31/2023 55292012252 NeoProfen Intravenous Solution 10 MG/ML Package Size 2 Package Quantity 3 Brand FDA 01/05/2023 280.32 3231.09 03/02/2032 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000363 Recordati Rare Diseases, inc. 03/31/2023 55292070255 Panhematin Intravenous Solution Reconstituted 350 MG Package Size 1 Quantity 1 Brand FDA 01/05/2023 751.08 10139.59 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000363 Recordati Rare Diseases, inc. 06/30/2023 55292013901 Signifor LAR Intramuscular Suspension Reconstituted ER 10 MG Brand FDA 06/23/2023 717.57 16663.56 05/23/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000363 Recordati Rare Diseases, inc. 03/31/2023 00078074881 Signifor LAR Intramuscular Suspension Reconstituted ER 10 MG Package Size 1 Quantity 1 Brand Medispan 01/05/2023 759.33 15945.99 05/23/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000363 Recordati Rare Diseases, inc. 03/31/2023 55292013901 Signifor LAR Intramuscular Suspension Reconstituted ER 10mg Package Size 1 Quantity 1 Brand FDA 01/05/2023 759.33 15945.99 05/23/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000363 Recordati Rare Diseases, inc. 06/30/2023 55292014001 Signifor LAR Intramuscular Suspension Reconstituted ER 20 MG Brand FDA 06/23/2023 717.57 16663.56 05/23/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000363 Recordati Rare Diseases, inc. 03/31/2023 00078064181 Signifor LAR Intramuscular Suspension Reconstituted ER 20 MG Package Size 1 Package Quantity 1 Brand Medispan 01/05/2023 759.33 15945.99 05/23/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000363 Recordati Rare Diseases, inc. 03/31/2023 55292014001 Signifor LAR Intramuscular Suspension Reconstituted ER 20mg Package Size 1 Quantity 1 Brand FDA 01/05/2023 759.33 15945.99 05/23/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000363 Recordati Rare Diseases, inc. 06/30/2023 55292014101 Signifor LAR Intramuscular Suspension Reconstituted ER 30 MG Brand FDA 06/23/2023 717.57 16663.56 05/23/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000363 Recordati Rare Diseases, inc. 03/31/2023 00078074181 Signifor LAR Intramuscular Suspension Reconstituted ER 30 MG Size 1 Package Quantity 1 Brand Medispan 01/05/2023 759.33 15945.99 05/23/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000363 Recordati Rare Diseases, inc. 03/31/2023 55292014101 Signifor LAR Intramuscular Suspension Reconstituted ER 30mg Package Size 1 Quantity 1 Brand FDA 01/05/2023 759.33 15945.99 05/23/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000363 Recordati Rare Diseases, inc. 06/30/2023 55292014201 Signifor LAR Intramuscular Suspension Reconstituted ER 40 MG Brand FDA 06/23/2023 717.57 16663.56 05/23/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000363 Recordati Rare Diseases, inc. 03/31/2023 00078064281 Signifor LAR Intramuscular Suspension Reconstituted ER 40 MG Size 1 Package Quantity 1 Brand Medispan 01/05/2023 759.33 15945.99 05/23/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000363 Recordati Rare Diseases, inc. 03/31/2023 55292014201 Signifor LAR Intramuscular Suspension Reconstituted ER 40mg Package Size 1 Quantity 1 Brand FDA 01/05/2023 759.33 15945.99 05/23/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000363 Recordati Rare Diseases, inc. 06/30/2023 55292014301 Signifor LAR Intramuscular Suspension Reconstituted ER 60 MG Brand FDA 06/23/2023 717.57 16663.56 05/23/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000363 Recordati Rare Diseases, inc. 03/31/2023 00078064381 Signifor LAR Intramuscular Suspension Reconstituted ER 60 MG Size 1 Package Quantity 1 Brand Medispan 01/05/2023 759.33 15945.99 05/23/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000363 Recordati Rare Diseases, inc. 03/31/2023 55292014301 Signifor LAR Intramuscular Suspension Reconstituted ER 60mg Package Size 1 Quantity 1 Brand FDA 01/05/2023 759.33 15945.99 05/23/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000363 Recordati Rare Diseases, inc. 06/30/2023 55292013160 Signifor Subcutaneous Solution 0.3 MG/ML Brand FDA 06/23/2023 755.92 17554.12 12/14/2026 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000363 Recordati Rare Diseases, inc. 03/31/2023 00078063320 Signifor Subcutaneous Solution 0.3 MG/ML Package size 1 Package Quantity 60 Brand Medispan 01/05/2023 799.91 16798.20 12/14/2026 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000363 Recordati Rare Diseases, inc. 03/31/2023 55292013160 Signifor Subcutaneous Solution 0.3MG Package Size 1 Package Quantity 60 Brand FDA 01/05/2023 799.91 16798.20 12/14/2026 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000363 Recordati Rare Diseases, inc. 06/30/2023 55292013260 Signifor Subcutaneous Solution 0.6 MG/ML Brand FDA 06/23/2023 755.92 17554.12 12/14/2026 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000363 Recordati Rare Diseases, inc. 03/31/2023 00078063420 Signifor Subcutaneous Solution 0.6 MG/ML Package size 1 Package Quantity 60 Brand Medispan 01/05/2023 799.91 16798.20 12/14/2026 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000363 Recordati Rare Diseases, inc. 03/31/2023 55292013260 Signifor Subcutaneous Solution 0.6MG Package Size 1 Package Quantity 60 Brand FDA 01/05/2023 799.91 16798.20 12/14/2026 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000363 Recordati Rare Diseases, inc. 06/30/2023 55292013360 Signifor Subcutaneous Solution 0.9 MG/ML Brand FDA 06/23/2023 755.92 17554.12 12/14/2026 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000363 Recordati Rare Diseases, inc. 03/31/2023 00078063520 Signifor Subcutaneous Solution 0.9 MG/ML Package size 1 Package Quantity 60 Brand Medispan 01/05/2023 799.91 16798.20 12/14/2026 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000363 Recordati Rare Diseases, inc. 03/31/2023 55292013360 Signifor Subcutaneous Solution 0.9MG Package Size 1 Package Quantity 60 Brand FDA 01/05/2023 799.91 16798.20 12/14/2026 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000166 Redhill Biopharma, Inc. 03/31/2023 57841115001 Talicia Oral Capsule Delayed Release 250-12.5-10 MG Brand FDA 01/01/2023 28.35 382.73 None Single Source Drug 21552 None Increased inflation costs and manufacturing agreement costs for product None None None None None None None None None None None None None None
Rx0000166 Redhill Biopharma, Inc. 03/31/2023 57841115002 Talicia Oral Capsule Delayed Release 250-12.5-10MG Brand FDA 01/01/2023 56.70 765.46 None Single Source Drug 21552 None Increased inflation costs and manufacturing agreement costs for product None None None None None None None None None None None None None None
Rx0000239 Rigel Pharmaceuticals, Inc. 03/31/2023 71332000101 Tavalisse 100 mg oral tablet 60 count Brand FDA 01/04/2023 780.00 13800.00 07/27/2032 Single Source Drug None 1 Rigel's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by Rigel to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None This WAC increase is not necessitated by a change or improvement in the prescription drug. None None None None None None None None None None None None
Rx0000239 Rigel Pharmaceuticals, Inc. 03/31/2023 71332000201 Tavalisse 150 mg oral tablet 60 count Brand FDA 01/04/2023 780.00 13800.00 07/27/2032 Single Source Drug None 1 Rigel's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by Rigel to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None This WAC increase is not necessitated by a change or improvement in the prescription drug. None None None None None None None None None None None None
Rx0000158 RISING PHARMA HOLDINGS, INC. 09/30/2023 70199002611 AQUASOL A PARENTERAL 50,000 Brand FDA 07/10/2023 143.75 718.75 None Single Source Drug 16368 None The last time the WAC was changed on the product was in 12/30/2020 which is approximately 2.5 years ago. This WAC change is 25% above the current WAC of $575. The is not a retail product and has very low usage. Even though the WAC has changed 07/10/2023 Casper has sold enough inventory at the previous WAC to support the trade for 60 days include wholesaler inventory and inventory in the channel. Casper has also implemented a state notification module with a third party vendor for timely filling and responses in the future. None The last time the WAC was changed on the product was in 12/30/2020 which is approximately 2.5 years ago. This WAC change is 25% above the current WAC of $575. The is not a retail product and has very low usage.Even though the WAC has changed 07/10/2023 Casper has sold enough inventory at the previous WAC to support the trade for 60 days include wholesaler inventory and inventory in the channel. Casper has also implemented a state notification module with a third party vendor for timely filling and responses in the future. None None None None None None None None None None None None
Rx0000158 RISING PHARMA HOLDINGS, INC. 12/31/2023 64980044715 CALCITRIOL ORAL SOL 1MCG/ML 15ML Generic FDA 11/14/2023 325.00 400.00 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000158 RISING PHARMA HOLDINGS, INC. 12/31/2023 64980058206 CHLORZOXAZONE TAB 250 MG 60CT Generic FDA 10/27/2023 489.68 1134.68 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000158 RISING PHARMA HOLDINGS, INC. 12/31/2023 16571060096 CROMOLYN SODIUM ORAL SOL CONC 100MG/5ML 96CT Generic FDA 11/13/2023 300.00 600.00 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000158 RISING PHARMA HOLDINGS, INC. 09/30/2023 64980052660 NITAZOXANIDE TABLETS 500MG 6CT Generic FDA 08/01/2023 429.30 780.55 None Non-innovator Multiple Source Drug None 1 Rising was the first company to receive an FDA approval for the generic equivalent to the brand (Alinia). The methodology used to price the new prescriptions drug was a discount on the brand equivalent. Rising's listed price i.e. WAC is priced 10.23% lower than the brand listed price. The price was decided on the fact that we are the first generic entrant in the market. The 6ct pack size price is in pill parity with the 12ct pack size. None None 1 None None None None None None None None None None None